<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006101</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 97-18 CDR0000068110</org_study_id>
    <secondary_id>U01CA8188601</secondary_id>
    <secondary_id>NCI-P00-0164</secondary_id>
    <secondary_id>NCI-2009-00890</secondary_id>
    <nct_id>NCT00006101</nct_id>
  </id_info>
  <brief_title>Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer</brief_title>
  <official_title>Randomized Placebo-Controlled, Double-Blind Phase IIb Chemoprevention Trial of Difluoromethylornithine in Brothers and First Cousin Males of Familial Prostate Cancer Probands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas E. Ahlering</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
      development of cancer. The use of eflornithine (DMFO) may be an effective way to prevent the
      development of prostate cancer.

      PURPOSE: Randomized phase II trial to determine the effectiveness of eflornithine in
      preventing prostate cancer in patients who are at high risk of developing the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the levels of polyamines (putrescine, spermidine, and spermine) and
           progression-related genes in the prostate tissue of patients at high genetic risk for
           prostate cancer treated with eflornithine (DFMO) vs placebo.

        -  Determine the side effects of DFMO and compare them with the biological effect on the
           prostate gland in these patients.

      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
      stratified according to age (35 to 60 vs 61 to 70) and presence of localized cancer (yes vs
      no).

      All patients receive oral placebo daily for 4 weeks. Patients who are compliant and take the
      placebo 5-7 days each week are randomized to one of two arms.

        -  Arm I: Patients receive oral placebo daily.

        -  Arm II: Patients receive high-dose oral eflornithine (DFMO) daily. Treatment continues
           for 1 year in the absence of unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 100 patients (50 per arm) will be accrued for this study within
      3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total PSA, Percent Free PSA, and Prostate Volume at 12 Months</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Difference refers to absolute difference of 12 months to baseline and % relative difference refers to the ratio of the absolute difference divided by the baseline times 100.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>eflornithine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500mg/d for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eflornithine</intervention_name>
    <description>Take 500mg of DFMO per day for 12 months</description>
    <arm_group_label>eflornithine</arm_group_label>
    <other_name>Difluoromethylornithine (DFMO)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take placebo per day for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for Eligibility

          1. Men between the ages of 35 and 70 with family history of prostate cancer, i.e.,
             prostate cancer diagnosed in two first degree relatives before the age of 70 years.
             (First degree relatives include a brother, father, and son.) There will be occasions
             in which a second or even third degree relative will be eligible. Additional
             information regarding these criteria is provided below and in Attachment 1.)

               -  Two or more affected relatives of which at least 1 is a first degree relative or

               -  At least two affected relatives, both of which are at least a second degree
                  relative or

               -  One first degree relative diagnosed with prostate cancer at age 55 or less.

          2. No history of invasive cancer within 5 years (though non-melanoma skin or papillary
             bladder cancer will not be reason to exclude a patient); no prior history of prostate
             cancer, no severe metabolic disorders or other life-threatening acute or chronic
             disease; no additional x-ray or chemotherapy anticipated.

               -  Men found to have localized prostate cancer (Gleason score ≤7) as part of the
                  screening for the current trial, and opt for watchful waiting as their standard
                  of care treatment for their condition, will be eligible to sign an additional
                  consent form to continue with the randomization and on-study activities of this
                  trial. On-study activities for these individuals will not differ from the
                  on-study activities for the other men enrolled in this trial.

          3. Must not require a medically mandated special diet which precludes compliance with
             study requirements

          4. Not requiring regular use of anticoagulants on a regular basis. Prior use of
             chemoprevention agent(s) (such as Proscar) is allowed as long as the subject has been
             off the agent(s) for at least 3 months. Not currently participating in another
             prostate prevention trial.

          5. Absence of history of current documented or symptomatic gastric or duodenal ulcer
             within 12 months prior to study entry, or of significant kidney or liver disease. No
             chronic anemia (hematocrit &lt; 35 volume %), leukopenia (WEB &lt;4,000) with normal
             differential, or thrombocytopenia (platelets &lt;100,000) and with serum creatinine &lt;1.5
             mg/dl, serum bilirubin &lt;2.0 mg/dl, and serum glutamic oxaloacetic transaminase (SGOT)
             or serum glutamic pyruvic transaminase (SGPT) &lt;2× normal. Urinalysis should have &lt;1+
             protein, 0-3 casts, 0-5 white blood cell count (WBC) and red blood cell count (RBC).

          6. Absence of any condition that predisposes to difficulties with hearing, wound healing
             or repair.

          7. Must meet Southwest Oncology Group performance status criteria of 0-1 (0 = fully
             active, able to carry on all predisease activities without restriction [Karnofsky
             scale 90-100]; 1 = restricted in physically strenuous activity, but ambulatory and
             able to carry out work of a light or sedentary nature, i.e., light housework or office
             work [Karnofsky scale 70-80].

          8. Subjects must be willing and able to keep required visits for study procedures and to
             complete study questionnaires.

          9. Patient must not have had radiation therapy in the pelvic area.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ahlering, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):292-9. doi: 10.1158/1055-9965.EPI-07-0658.</citation>
    <PMID>18268112</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>February 7, 2018</results_first_submitted>
  <results_first_submitted_qc>March 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2018</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Thomas E. Ahlering</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eflornithine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eflornithine</title>
          <description>500mg/d for 12 months
eflornithine: Take 500mg of eflornithine (Difluoromethylornithine) per day for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo for 12 months
Placebo: Take placebo per day for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eflornithine</title>
          <description>500mg/d for 12 months
eflornithine: Take 500mg of DFMO per day for 12 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo for 12 months
Placebo: Take placebo per day for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total PSA, Percent Free PSA, and Prostate Volume at 12 Months</title>
        <description>Difference refers to absolute difference of 12 months to baseline and % relative difference refers to the ratio of the absolute difference divided by the baseline times 100.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>The results reported include all men with both an entrance and exit biopsy, regardless of cancer status.</population>
        <group_list>
          <group group_id="O1">
            <title>Eflornithine</title>
            <description>500mg/d for 12 months
eflornithine: Take 500mg of DFMO per day for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo for 12 months
Placebo: Take placebo per day for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total PSA, Percent Free PSA, and Prostate Volume at 12 Months</title>
          <description>Difference refers to absolute difference of 12 months to baseline and % relative difference refers to the ratio of the absolute difference divided by the baseline times 100.</description>
          <population>The results reported include all men with both an entrance and exit biopsy, regardless of cancer status.</population>
          <units>Relative % difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total PSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="26.29"/>
                    <measurement group_id="O2" value="1.55" spread="38.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Free PSA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.21" spread="44.39"/>
                    <measurement group_id="O2" value="4.89" spread="40.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="17.58"/>
                    <measurement group_id="O2" value="11.14" spread="19.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eflornithine</title>
          <description>500mg/d for 12 months
eflornithine: Take 500mg of DFMO per day for 12 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo for 12 months
Placebo: Take placebo per day for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer Diagnosis</sub_title>
                <description>Diagnosed at 6 or 12 month biopsy</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee Replacement</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Hospitalized for full knee replacement</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Side Effects</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Flu or cold symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular skeletal complaints</sub_title>
                <description>Complaints include disk disease, tendonitis, etc.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing Related Complaints</sub_title>
                <description>Include tinnitus, vertigo, and hearing changes</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual Difficulties</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Ahlering</name_or_title>
      <organization>University of California, Irvine</organization>
      <phone>(714) 456-6068</phone>
      <email>tahlerin@uci.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

